Browse News
Filter News
Found 4 articles
-
Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs
2/2/2023
Mindset Pharma Inc. announced today that the United States Patent and Trademark Office (“USPTO”) has granted allowance for another of Mindset’s Family 1 patent applications, number 17/743,718, titled “Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”
-
Mindset Pharma Receives Allowance for U.S. Patent Application Covering Composition of Matter for Its Lead Psychedelic Therapeutic Candidate, MSP-1014, And Additional Family 1 Tryptamine Prodrug Candidates
1/20/2023
Mindset Pharma Inc. announced today that the United States Patent and Trademark Office (“USPTO”) has granted allowance for Mindset’s patent application number 17/833,341, titled “Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”
-
Mindset Pharma was granted allowance by the U.S. Patent and Trademark Office for its application for a psilocybin-based family of drugs to treat central nervous system disorders.
-
Mindset Pharma Receives Notice of Allowance for Patent Application Covering Psilocin Derivatives for the Treatment of Central Nervous System Disorders
6/10/2022
Mindset Pharma Inc. today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for Mindset’s patent application number 17/387,845.